Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...

Viatris has faced volatility since its 2020 formation but is now in Phase 2 of its transformation. Learn why VTRS stock could ...

These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

World-recognized brand Pfizer has agreed to a nearly $60 million financial agreement to settle claims that a wholly-owned ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Drugmakers raised the prices of more than 800 prescription drugs for blood pressure, cancer, and other conditions by 4% at the beginning of the ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

Havas Health Network has rebranded a U.K. agency. Havas Life Medicom is now Havas Life London, a group focused on brand, ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.